Kyverna Therapeutics Inc KYTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Kyverna Therapeutics Presents Patient Data Reinforcing Potential of KYV-101 for Treatment of Neuroinflammatory Diseases in Symposium at ECTRIMS 2024
-
Kyverna Therapeutics Announces Leadership Update
-
Kyverna Therapeutics to Participate in Upcoming September Investor Conferences
-
Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
-
Kyverna Therapeutics Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Progressive Myasthenia Gravis
-
Kyverna Shares Rise After FDA Gives Special Designation to Stiff-Person Treatment
-
Kyverna's KYV-101 Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Refractory Stiff-Person Syndrome
-
Kyverna Therapeutics Shares Rise 13% After FDA Clearance for KYV-101
Trading Information
- Previous Close Price
- $5.25
- Day Range
- $5.15–5.35
- 52-Week Range
- $5.15–35.06
- Bid/Ask
- $5.23 / $5.23
- Market Cap
- $225.66 Mil
- Volume/Avg
- 411,793 / 472,016
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 112
- Website
- https://www.kyvernatx.com
Comparables
Valuation
Metric
|
KYTX
|
CGON
|
TCRX
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.68 | 4.57 | 1.05 |
Price/Sales | — | 252.33 | 41.24 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
Metric
|
KYTX
|
CGON
|
TCRX
|
---|---|---|---|
Quick Ratio | 14.75 | 46.66 | 7.72 |
Current Ratio | 14.86 | 47.57 | 7.77 |
Interest Coverage | −558.59 | — | −29.80 |
Quick Ratio
KYTX
CGON
TCRX
Profitability
Metric
|
KYTX
|
CGON
|
TCRX
|
---|---|---|---|
Return on Assets (Normalized) | −37.69% | −15.24% | −32.50% |
Return on Equity (Normalized) | −76.90% | −26.61% | −54.73% |
Return on Invested Capital (Normalized) | −77.97% | −25.60% | −39.01% |
Return on Assets
KYTX
CGON
TCRX
Biotechnology Industry Comparables
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|---|
Novo Nordisk AS ADR
NVO
| Qyzphxrkn | Qkpqx | $531.4 Bil | |||
Vertex Pharmaceuticals Inc
VRTX
| Zkgmwqkq | Rmwkmg | $119.5 Bil | |||
Regeneron Pharmaceuticals Inc
REGN
| Nqbfqlfk | Tgsrlp | $114.9 Bil | |||
Alnylam Pharmaceuticals Inc
ALNY
| Glmsrlyx | Hpcmn | $35.3 Bil | |||
argenx SE ADR
ARGX
| Whbbsjbg | Cymvq | $32.0 Bil | |||
BioNTech SE ADR
BNTX
| Stncjpyf | Lsyh | $28.1 Bil | |||
Moderna Inc
MRNA
| Jzchghp | Cxjd | $25.3 Bil | |||
United Therapeutics Corp
UTHR
| Kqnsvycq | Mhtc | $16.0 Bil | |||
Biomarin Pharmaceutical Inc
BMRN
| Pnlxmmh | Zlnrf | $13.4 Bil | |||
Incyte Corp
INCY
| Nrpsmtbx | Dskrqp | $12.7 Bil |